NEXENTIS TECHNOLOGIES INC. Fair Value Adjustment of Warrants
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Fair Value Adjustment of Warrants of $7.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $7.56M.
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$50.00K, a 148.54% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$104.00K.
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$224.00K.
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for fiscal 2025 was -$234.00K, a 4780.00% decline from fiscal 2024.
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for fiscal 2024 was $5.00K.
- NEXENTIS TECHNOLOGIES INC. fair value adjustment of warrants for fiscal 2019 was $157.99K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.51M 10-Q · filed 2026-08-13 | $7.40M derived: sum of 3 quarters · filed 2026-08-13 | $7.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$50.00K 10-Q · filed 2026-05-14 | -$154.00K derived: sum of 2 quarters · filed 2026-05-14 | -$378.00K derived: sum of 3 quarters · filed 2026-05-14 | -$387.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$328.00K derived: sum of 2 quarters · filed 2026-03-31 | -$337.00K derived: sum of 3 quarters · filed 2026-08-13 | -$234.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$224.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$233.00K derived: sum of 2 quarters · filed 2026-08-13 | -$130.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $94.00K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $103.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $5.00K 10-K · filed 2026-03-31 | |||
| 2019-12-31 | $157.99K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |